IN2012DN00570A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00570A
IN2012DN00570A IN570DEN2012A IN2012DN00570A IN 2012DN00570 A IN2012DN00570 A IN 2012DN00570A IN 570DEN2012 A IN570DEN2012 A IN 570DEN2012A IN 2012DN00570 A IN2012DN00570 A IN 2012DN00570A
Authority
IN
India
Prior art keywords
biodegradable polymer
compositions
present
matrix
methods
Prior art date
Application number
Inventor
Noam Emanuel
Moshe Neuman
Shlomo Barak
Original Assignee
Polypid Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polypid Ltd filed Critical Polypid Ltd
Publication of IN2012DN00570A publication Critical patent/IN2012DN00570A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)

Abstract

The present invention provides compositions for extended release of one or more active ingredients, comprising a lipid-saturated matrix formed from a non-biodegradable polymer or a block- co-polymers comprising a non-biodegradable polymer and a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
IN570DEN2012 2009-07-14 2010-07-14 IN2012DN00570A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22528909P 2009-07-14 2009-07-14
PCT/IL2010/000563 WO2011007353A1 (en) 2009-07-14 2010-07-14 Sustained-release drug carrier composition

Publications (1)

Publication Number Publication Date
IN2012DN00570A true IN2012DN00570A (en) 2015-06-12

Family

ID=43448999

Family Applications (1)

Application Number Title Priority Date Filing Date
IN570DEN2012 IN2012DN00570A (en) 2009-07-14 2010-07-14

Country Status (9)

Country Link
US (2) US8992979B2 (en)
EP (1) EP2453877B1 (en)
JP (1) JP5738856B2 (en)
CN (2) CN102470105B (en)
AU (1) AU2010272167B2 (en)
CA (1) CA2767973C (en)
ES (1) ES2732149T3 (en)
IN (1) IN2012DN00570A (en)
WO (1) WO2011007353A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12181602B2 (en) 2021-02-01 2024-12-31 Hitachi Rail Gts Canada Inc. Systems and methods of calibrating a range measurement system

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2299953T3 (en) 2008-07-14 2017-06-19 Polypid Ltd CARBON COMPOSITION FOR MEDICINAL PRODUCTS WITH CONTINUOUS EXPOSURE
CN102892406B (en) 2010-01-19 2015-04-08 波利皮得有限公司 Sustained-release nucleic acid matrix compositions
US20140271861A1 (en) * 2011-07-27 2014-09-18 Polypid Ltd. Matrix compositions for controlled release of peptide and polypeptide molecules
WO2013146788A1 (en) * 2012-03-27 2013-10-03 国立大学法人名古屋大学 Three-dimensional structure created from material comprising polyhydroxyalkanoate, kit for preparing bone filling material, and intramedullary nail
ES2802025T3 (en) * 2012-08-02 2021-01-15 Polypid Ltd Compositions and methods for the treatment of bone voids and open fractures
EP2919823B1 (en) * 2012-11-14 2019-07-03 Orthopaedic Innovation Centre Inc. Antimicrobial articles produced by additive manufacturing
US9775853B2 (en) 2013-03-15 2017-10-03 Biomet Manufacturing, Llc. Hemostatic compositions and methods
AR101476A1 (en) 2014-08-07 2016-12-21 Acerta Pharma Bv METHODS TO TREAT CANCER, IMMUNE AND AUTO-IMMUNE DISEASES, AND INFLAMMATORY DISEASES BASED ON THE OCCUPATION RATE OF THE BRUTON TYPOSIN QUINASE (BTK) AND THE RESULTS OF THE TIROSIN QUINASK (TUTOSIN QUINASK)
JP6526400B2 (en) * 2014-09-11 2019-06-05 サンスター株式会社 Oral composition
WO2016051322A1 (en) * 2014-10-02 2016-04-07 Polypid Ltd. Methods for the treatment of peri-implantitis
PT3200748T (en) * 2014-10-02 2021-12-27 Polypid Ltd Compositions and methods for the treatment and prophylaxis of surgical site infections
US10792477B2 (en) 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
EP3868434A1 (en) * 2016-02-08 2021-08-25 Orbusneich Medical Pte. Ltd Drug eluting balloon
CN106146761A (en) * 2016-06-03 2016-11-23 西北大学 The nano-micelle of a kind of amphipathic multifunctional polymer and preparation thereof and application
JP7102423B2 (en) * 2017-02-16 2022-07-19 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド Liposomal drug delivery vehicle
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
KR20260007295A (en) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 Implantable device for sustained release of a macromolecular drug compound
MX2022000203A (en) 2019-07-03 2022-03-22 Atossa Therapeutics Inc ENDOXYPHENE SUSTAINED RELEASE COMPOSITIONS.
CN113081482B (en) * 2021-04-23 2024-02-27 柏为（武汉）医疗科技股份有限公司 Middle ear anti-adhesion membrane and preparation method thereof
BR112023022439A2 (en) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc IMPLANTABLE DEVICE FOR SUSTAINED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
CN113702647B (en) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 Human growth differentiation factor 15 instant detection kit, preparation method and application thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4882167A (en) 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4578384A (en) 1984-02-15 1986-03-25 The United States Of America As Represented By The Secretary Of The Army Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue
JPS6163613A (en) 1984-09-04 1986-04-01 Mitsui Toatsu Chem Inc Sustained release preparation
US5043166A (en) 1987-01-09 1991-08-27 Hadasit Medical Research, Inc. Liposome/anthraquinone drug composition and method
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
ES2085465T3 (en) 1989-11-13 1996-06-01 Abraham J Domb LIPOESFERAS FOR THE CONTROLLED ADMINISTRATION OF SUBSTANCES.
US6120805A (en) 1990-04-06 2000-09-19 Rhone-Poulenc Rorer Sa Microspheres, process for their preparation and their use
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US6156337A (en) 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5919480A (en) 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US5837221A (en) 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
WO1998007412A1 (en) 1996-08-21 1998-02-26 Alkermes Controlled Therapeutics, Inc. Controlled release microparticles with a hydrophobic material
WO1998010798A1 (en) 1996-09-11 1998-03-19 Imarx Pharmaceutical Corp. Improved methods for diagnostic imaging using a contrast agent and a vasodilator
US6048551A (en) 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
US6248345B1 (en) 1997-07-02 2001-06-19 Euro-Celtique, S.A. Prolonged anesthesia in joints and body spaces
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
JP4545928B2 (en) 1998-04-27 2010-09-15 ジリップ・ファーマ・ビー．ブイ． Pharmaceutical composition containing factor VIII and neutral liposomes
US6423345B2 (en) 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
AU752225B2 (en) 1998-07-17 2002-09-12 Pacira Pharmaceuticals, Inc. Biodegradable compositions for the controlled release of encapsulated substances
CA2340118C (en) 1998-08-12 2009-01-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US6083482A (en) 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
AU5624500A (en) 1999-06-18 2001-01-09 Collaborative Group, Ltd., The Hyaluronic acid microspheres for sustained gene transfer
DE10001172A1 (en) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templating solid particles with polymer multilayers
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
EP1324778A2 (en) * 2000-10-02 2003-07-09 Arizeke Pharmaceuticals, Inc. Compositions and methods for the transport of biologically active agents across cellular barriers
FI20010540A0 (en) 2001-03-16 2001-03-16 Yli Urpo Antti Composite for the correction of defects in soft and hard tissue and the use of said composite
CA2461616A1 (en) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
TWI226249B (en) 2001-12-19 2005-01-11 Ind Tech Res Inst Biodegradable composite matrix for enhancing angiogenesis
WO2003097805A2 (en) 2002-05-15 2003-11-27 California Pacific Medical Center Delivery of nucleic acid-like compounds
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
JP5508661B2 (en) * 2003-02-12 2014-06-04 シンセラ インコーポレイテッド Random and non-random alkylene oxide polymer alloy compositions
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
US8097273B2 (en) 2003-04-10 2012-01-17 Teijin Limited Biodegradable film having honeycomb structure
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20060188573A1 (en) * 2003-06-10 2006-08-24 Anna Imberg Composite materials and particles
US20050249697A1 (en) 2003-09-24 2005-11-10 Uhrich Kathryn E Compositions and methods for the inhibition of bone growth and resorption
WO2005117830A1 (en) * 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
JP4647497B2 (en) 2003-11-21 2011-03-09 帝人株式会社 Tissue regeneration substrate, cell complex and method for producing the same
EP1706149A2 (en) 2004-01-15 2006-10-04 Alza Corporation Liposome composition for delivery of therapeutic agents
US8277831B2 (en) * 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
US7744644B2 (en) 2004-03-19 2010-06-29 Boston Scientific Scimed, Inc. Medical articles having regions with polyelectrolyte multilayer coatings for regulating drug release
DE102004025495A1 (en) * 2004-05-21 2005-12-15 Dr. Suwelack Skin & Health Care Ag Process for the production of alginate-containing porous moldings
US20050287180A1 (en) * 2004-06-15 2005-12-29 Chen Andrew X Phospholipid compositions and methods for their preparation and use
CA2578709C (en) 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
MX2007000979A (en) 2004-07-26 2007-07-11 Cotherix Inc Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation.
US8790672B2 (en) * 2005-02-22 2014-07-29 Nina M. Lamba-Kohli Generation of antimicrobial surfaces using dendrimer biocides
MX2007013213A (en) 2005-04-25 2007-12-12 Amgen Inc Biodegradable peptide sustained release compositions containing porogens.
US20070141134A1 (en) 2005-12-16 2007-06-21 Kosak Matthew K Shielded micelles for polynucleotide delivery
US20090318355A1 (en) 2006-02-15 2009-12-24 Chen Thomas T Compositions and methods for promoting tissue repair and wound healing
ES2776100T3 (en) 2006-03-31 2020-07-29 Massachusetts Inst Technology System for targeted delivery of therapeutic agents
US8703167B2 (en) * 2006-06-05 2014-04-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
JP2009540965A (en) * 2006-06-21 2009-11-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Compositions and methods for joining unbound lumens
CN101209243B (en) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 Liposome medicament and preparation thereof
CA2679316C (en) 2007-03-02 2016-11-29 Teika Pharmaceutical Co., Ltd. Morphine composition for transdermal absorption, morphine composition storing unit and transdermal absorption preparation using the same
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
US20090110713A1 (en) 2007-10-31 2009-04-30 Florencia Lim Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices
WO2009061515A1 (en) 2007-11-09 2009-05-14 Northeastern University Self-assembling micelle-like nanoparticles for systemic gene delivery
US20110027172A1 (en) 2007-12-10 2011-02-03 Zhuang Wang Drug delivery system for pharmaceuticals and radiation
US8128983B2 (en) 2008-04-11 2012-03-06 Abbott Cardiovascular Systems Inc. Coating comprising poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
DK2299953T3 (en) 2008-07-14 2017-06-19 Polypid Ltd CARBON COMPOSITION FOR MEDICINAL PRODUCTS WITH CONTINUOUS EXPOSURE
WO2010078517A2 (en) 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
WO2010135207A1 (en) 2009-05-16 2010-11-25 Agave Pharma, Incorporated Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules
CN102892406B (en) 2010-01-19 2015-04-08 波利皮得有限公司 Sustained-release nucleic acid matrix compositions
IN2014DN05640A (en) * 2012-01-10 2015-04-03 Elevance Renewable Sciences

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12181602B2 (en) 2021-02-01 2024-12-31 Hitachi Rail Gts Canada Inc. Systems and methods of calibrating a range measurement system

Also Published As

Publication number Publication date
CA2767973C (en) 2019-06-18
AU2010272167A1 (en) 2012-02-02
US10463617B2 (en) 2019-11-05
EP2453877B1 (en) 2019-05-08
US8992979B2 (en) 2015-03-31
CN102470105B (en) 2015-07-29
JP2012533334A (en) 2012-12-27
CN105126179A (en) 2015-12-09
CA2767973A1 (en) 2011-01-20
JP5738856B2 (en) 2015-06-24
EP2453877A4 (en) 2013-05-29
US20120114756A1 (en) 2012-05-10
CN102470105A (en) 2012-05-23
EP2453877A1 (en) 2012-05-23
AU2010272167B2 (en) 2016-11-17
US20150174073A1 (en) 2015-06-25
ES2732149T3 (en) 2019-11-20
WO2011007353A1 (en) 2011-01-20
CN105126179B (en) 2018-09-25

Similar Documents

Publication Publication Date Title
IN2012DN00570A (en)
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
MX2010003299A (en) Micromirs.
WO2010017215A3 (en) Biodegradable microspheres and methods of use thereof
BRPI0917017B8 (en) s-nitrosoglutathione reductase pyrrole inhibitors as therapeutic agents
IL211541A0 (en) Co-crystal compositions, methods of producing the same and uses thereof
EP2305209A3 (en) Composition comprising a polyol,a sugar silicone surfactant and an oil-soluble high carbon polar modified polymer
EP2488023A4 (en) Antimicrobial composition
WO2010125475A3 (en) Sustained release formulations comprising gnrh analogues
WO2011003902A3 (en) Multimodal visible polymer embolization material
WO2008087215A3 (en) Partially bioabsorbable implant
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
EP2395048A3 (en) Polymers compositions including an antioxidant
WO2011089595A3 (en) Sustained-release nucleic acid matrix compositions
MX2011012504A (en) Pyrazinylpyrazoles.
BRPI1011188A2 (en) dermal release compositions comprising calcium phosphate-active agent particle complexes and methods for using them.
MX2009006033A (en) Composition and articles containing cross-liinked polymer matrix and immobilized active liquid, and methods of making same.
UA86731C2 (en) Divisible galenic form of the modified drug release
UA103025C2 (en) Solid pharmaceutical formulation with delayed release
MX2012008930A (en) Ethanol compositions.
MX2012007365A (en) Slow release pharmaceutical compositions of iloperidone.
IN2012DN03404A (en)
HK1199841A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2011035013A3 (en) Implant devices that differ by release profile and methods of making and using same
MX349563B (en) Pharmaceutical formulation of nanonised fenofibrate.